ToxMinds supports a large, multinational cosmetic product manufacturer in prioritising new molecules for use in cosmetic applications from a consumer safety point of view.
Over a number of years, we have been working closely with a multinational cosmetic product manufacturer in the context of qualifying upstream R&D molecules for use in their cosmetic product lines from a consumer safety point of view. This work is specifically challenging as the EU Cosmetics Regulation does not permit the use of any in vivo data for safety assessment purposes that have been generated after March 2013. Moreover, non-animal methodologies to address systemic toxicity endpoints following repeated exposure are still scarce. Considering that exposure-based waivers or TTC-type of approaches rarely help support anticipated in-use concentrations, our client particularly valued our innovative thinking and use of new risk assessment methodologies in the process. Clearly, we do not always find ways to support the molecules under consideration, but quite often we do. Our optimised analogue identification methodologies paired with our proposals for testing strategies to tie source and target substances closer strengthen the read-across cases significantly.